<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437265</url>
  </required_header>
  <id_info>
    <org_study_id>NER1006-03/2016 (PKPU)</org_study_id>
    <secondary_id>2017-003440-20</secondary_id>
    <nct_id>NCT03437265</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of PLENVU® in Healthy Subjects</brief_title>
  <acronym>PKPU</acronym>
  <official_title>A Pharmacokinetic Study of PLENVU® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study characterises the pharmacokinetic (PK) profile of the active ingredients of PLENVU&#xD;
      (NER1006) and their related substances/metabolites. Subjects will receive PLENVU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PLENVU is a novel, low volume (1 L) PEG 3350 and ascorbate based bowel preparation that has&#xD;
      been developed to provide whole bowel cleansing. Studies have shown that formulating the&#xD;
      osmotically active agents sodium ascorbate/ascorbic acid (also known as vitamin C) and sodium&#xD;
      sulfate in combination with PEG 3350 enable a reduction in the volume of the PEG-based lavage&#xD;
      solution.&#xD;
&#xD;
      PLENVU has a dual formulation containing an initial majority PEG dose followed by a majority&#xD;
      ascorbate dose to maximise the overall effectiveness. This novel formulation addresses the&#xD;
      challenges faced by patients to comply with drinking higher volume, 2 and 3 L, preparations.&#xD;
&#xD;
      The purpose of this study is to determine if there is systemic exposure to components of the&#xD;
      PLENVU formulation (PEG 3350, ascorbate and potential related substances/metabolites (oxalic&#xD;
      acid, glycolic acid, ethylene glycol and diethylene glycol).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>Time of maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the pharmacokinetic (PK) population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>Apparent elimination half-life (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>The mean maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From 0 Time to 24 h Post-dose (AUC[0-24]) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>Area under the curve from 0 time to 24 h post-dose (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-last) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>Area under the curve from 0 time to the last measurable concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</measure>
    <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
    <description>Area under the curve from 0 time extrapolated to infinity (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing and Number of Bowel Movements</measure>
    <time_frame>Start of dose 1 to 60 hours</time_frame>
    <description>Pharmacodynamic outcome. The time of each bowel movement will be recorded for each subject, and the number of bowel movements after each dose per subject will be derived.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Clear Effluent</measure>
    <time_frame>Start of dose 1 to 60 hours</time_frame>
    <description>Pharmacodynamic outcome. Scoring was according to a 4-point scale (adapted from the stool characteristics rating tool described by Hsu et al, Adv Dig Med. 2016; 3 (3):144-147).&#xD;
A. Clear contents (may be coloured but able to visualise the bottom of the toilet bowl) B. Turbid contents C. Opaque contents (dark and murky) D. Any solid/semi-solid faecal material (irrespective of size) in the toilet bowl</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>PLENVU powder for oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1: Oral administration of 1 sachet (115.96 g) PLENVU Dose 1, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 1.&#xD;
Dose 2: Oral administration of 2 sachets (101.91 g) comprising PLENVU Dose 2, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 2.&#xD;
Additional water was permitted ad libitum during and after each dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLENVU powder for oral solution</intervention_name>
    <description>PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)</description>
    <arm_group_label>PLENVU powder for oral solution</arm_group_label>
    <other_name>NER1006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or non-pregnant, non-lactating healthy females&#xD;
&#xD;
          2. Age 18 to 30 years&#xD;
&#xD;
          3. BMI of 18.0 to 35.0 kg/m2&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study&#xD;
&#xD;
          5. Must provide written informed consent&#xD;
&#xD;
          6. Must agree to use an adequate method of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any Investigational Medicinal Product (IMP) in a clinical&#xD;
             research study within the previous 3 months&#xD;
&#xD;
          2. Subjects who are study site employees, or immediate family members of a study site or&#xD;
             sponsor employee&#xD;
&#xD;
          3. Subjects who have previously been enrolled in this study.&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          5. Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week&#xD;
             (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)&#xD;
&#xD;
          6. Current smokers and those who have smoked within the last 12 months. A breath carbon&#xD;
             monoxide reading of greater than 10 ppm at screening&#xD;
&#xD;
          7. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          8. Females who are pregnant or lactating (all female subjects must have a negative urine&#xD;
             pregnancy test at screening and admission).&#xD;
&#xD;
          9. Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator at screening&#xD;
&#xD;
         10. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by&#xD;
             the investigator at screening&#xD;
&#xD;
         11. Evidence of dehydration or abnormal electrolyte levels. Clinical evidence or suspicion&#xD;
             of significant dehydration at admission/pre-dose.&#xD;
&#xD;
         12. History or evidence of any clinically relevant ECG abnormality and hypertension&#xD;
&#xD;
         13. Positive drugs of abuse test result&#xD;
&#xD;
         14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) results&#xD;
&#xD;
         15. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or psychiatric disorder, as judged by the investigator&#xD;
&#xD;
         16. History or presence of organic or functional gastrointestinal conditions (e.g. chronic&#xD;
             constipation, inflammatory bowel disease or irritable bowel syndrome)&#xD;
&#xD;
         17. Previous or current relevant abnormal gastrointestinal motility according to clinical&#xD;
             judgement&#xD;
&#xD;
         18. History or presence of any clinically significant acute illness within 28 days prior&#xD;
             to the first dose of IMP based on clinical judgement at screening or admission&#xD;
&#xD;
         19. History of any of the contraindications mentioned in the PLENVU Summary of Product&#xD;
             Characteristics (SmPC)&#xD;
&#xD;
         20. Clinically relevant findings on physical examination based on investigator judgement&#xD;
&#xD;
         21. Donation or loss of greater than 500 mL of blood within the previous 8 weeks&#xD;
&#xD;
         22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other&#xD;
             than hormonal contraception and occasional use of non-steroidal anti-inflammatory&#xD;
             drugs [NSAIDs] and paracetamol) or herbal remedies in the 28 days before IMP&#xD;
             administration Exceptions may apply on a case by case basis, if considered not to&#xD;
             interfere with the objectives of the study, as agreed by the PI and sponsor's medical&#xD;
             monitor.&#xD;
&#xD;
         23. Use of laxatives and gastrointestinal motility altering drug in the last 3 months&#xD;
&#xD;
         24. Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection&#xD;
&#xD;
         25. Subjects who are ordered to live in an institution on court or authority order&#xD;
&#xD;
         26. Failure to satisfy the investigator of fitness to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MBChB, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences (Quotient),</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 3, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03437265/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Healthy adult subjects given PLENVU powder for oral solution: PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy adult subjects who recieved at least a partial dose of PLENVU</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All subjects who received at least a partial dose of IMP</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" lower_limit="19" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index weight in kg/ height in m2</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.85" spread="3.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Height in cm</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Weight in kg</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.82" spread="17.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>Time of maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the pharmacokinetic (PK) population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>Time of maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the pharmacokinetic (PK) population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.97" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="4.00" upper_limit="36.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>T1/2 (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>Apparent elimination half-life (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2 (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>Apparent elimination half-life (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.62" spread="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>The mean maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>The mean maximum observed concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1010" spread="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528" spread="113.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic Acid (μg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From 0 Time to 24 h Post-dose (AUC[0-24]) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>Area under the curve from 0 time to 24 h post-dose (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From 0 Time to 24 h Post-dose (AUC[0-24]) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>Area under the curve from 0 time to 24 h post-dose (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7220" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3820" spread="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid (μg.h/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-last) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>Area under the curve from 0 time to the last measurable concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-last) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>Area under the curve from 0 time to the last measurable concentration (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7140" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9020" spread="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid (μg.h/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-inf) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
        <description>Area under the curve from 0 time extrapolated to infinity (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
        <time_frame>Blood samples were taken pre-dose and up to 60 hours after start of Dose 1</time_frame>
        <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-inf) (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid)</title>
          <description>Area under the curve from 0 time extrapolated to infinity (of PEG3350, and glycolic acid and ascorbic acid corrected for baseline levels), calculated from individual plasma concentrations of the PK population.</description>
          <population>PK population 1: all evaluable subjects who had a minimum of 1 valid post-dose analytical result for PK parameter estimation and who satisfied the following criterion for at least 1 profile: no relevant protocol deviations which may have impacted the study objectives with respect to the PK endpoints.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEG 3350</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7340" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gycolic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6900" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascorbic acid (μg.h/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>PK parameters were estimated for each subject by non-compartmental analysis methods using Phoenix® WinNonlin® software (v8.0, Certara USA, Inc., USA). Summary statistics (n, mean, SD, CV%, median, minimum, maximum, geometric n, geometric mean (geometric SD) and geometric CV%) were presented. The Geometric CV for glycolic acid was Not Calculated (appears as 0%).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timing and Number of Bowel Movements</title>
        <description>Pharmacodynamic outcome. The time of each bowel movement will be recorded for each subject, and the number of bowel movements after each dose per subject will be derived.</description>
        <time_frame>Start of dose 1 to 60 hours</time_frame>
        <population>Pharmacodynamic (PD) analysis set: subjects who received both doses and had sufficient PD data for at least 1 time point</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Timing and Number of Bowel Movements</title>
          <description>Pharmacodynamic outcome. The time of each bowel movement will be recorded for each subject, and the number of bowel movements after each dose per subject will be derived.</description>
          <population>Pharmacodynamic (PD) analysis set: subjects who received both doses and had sufficient PD data for at least 1 time point</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-6 hours</title>
              <category_list>
                <category>
                  <title>0 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 bowel movement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 12 hours</title>
              <category_list>
                <category>
                  <title>0 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 bowel movement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 24 hours</title>
              <category_list>
                <category>
                  <title>0 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 bowel movement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 - 48 hours</title>
              <category_list>
                <category>
                  <title>0 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 bowel movement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 - 60 hours</title>
              <category_list>
                <category>
                  <title>0 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 bowel movement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥10 bowel movements</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>Summary of the number of bowel movements per time period for the PD analysis set</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Clear Effluent</title>
        <description>Pharmacodynamic outcome. Scoring was according to a 4-point scale (adapted from the stool characteristics rating tool described by Hsu et al, Adv Dig Med. 2016; 3 (3):144-147).&#xD;
A. Clear contents (may be coloured but able to visualise the bottom of the toilet bowl) B. Turbid contents C. Opaque contents (dark and murky) D. Any solid/semi-solid faecal material (irrespective of size) in the toilet bowl</description>
        <time_frame>Start of dose 1 to 60 hours</time_frame>
        <population>PD (pharmacodynamic) analysis set: subjects who received both doses and had sufficient PD data for at least 1 time point</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All subjects who received at least a partial dose of IMP.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Clear Effluent</title>
          <description>Pharmacodynamic outcome. Scoring was according to a 4-point scale (adapted from the stool characteristics rating tool described by Hsu et al, Adv Dig Med. 2016; 3 (3):144-147).&#xD;
A. Clear contents (may be coloured but able to visualise the bottom of the toilet bowl) B. Turbid contents C. Opaque contents (dark and murky) D. Any solid/semi-solid faecal material (irrespective of size) in the toilet bowl</description>
          <population>PD (pharmacodynamic) analysis set: subjects who received both doses and had sufficient PD data for at least 1 time point</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to clear effluent (A)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.0" lower_limit="98" upper_limit="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to turbid contents (B)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.5" lower_limit="58" upper_limit="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>The time (in minutes) to achieve clear effluent/time to turbid contents is presented for the PD analysis set.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening (Day -28 to -2) to post study follow-up (Day 6 to 8)</time_frame>
      <desc>Adverse Events were recorded from the time of providing written informed consent until discharge from the study at the follow-up visit/call. During each study visit, subjects were questioned directly regarding the occurrence of any adverse medical event according to the schedule in the clinical database.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>All subjects who received at least a partial dose of IMP.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreement between Norgine and Quotient Sciences states that Quotient have no publication rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In addition to PEG 3350, glycolic acid and ascorbic acid, PK parameters were to be determined for oxalic acid, ethylene glycol and diethylene glycol. However, this was not done, as no quantifiable concentrations of oxalic acid (LLOQ &lt;10.0 μg/mL), diethylene glycol (LLOQ &lt;2.50 μg/mL), or ethylene glycol (LLOQ &lt;2.50 μg/mL) were observed.&#xD;
Diarrhoea was expected as it is the intended pharmacodynamic effect of PLENVU bowel preparation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lucy Clayton</name_or_title>
      <organization>Norgine</organization>
      <phone>+441895826669</phone>
      <email>LClayton@norgine.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

